Pal Andre Holme
Overview
Explore the profile of Pal Andre Holme including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reding M, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, et al.
Drugs R D
. 2024 Dec;
PMID: 39702563
No abstract available.
2.
Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme P, Alvarez-Roman M, et al.
Eur J Haematol
. 2024 Oct;
114(2):248-257.
PMID: 39434416
Objectives: The 24-month, prospective, non-interventional, European multicenter A-SURE study evaluated the real-world effectiveness of prophylaxis using an extended half-life recombinant factor VIII (FVIII) Fc fusion protein, efmoroctocog alfa (hereinafter rFVIIIFc),...
3.
Qvigstad C, Sorensen L, Tjonnfjord G, Holme P
Res Pract Thromb Haemost
. 2024 Aug;
8(5):102514.
PMID: 39188890
Background: People with hemophilia often experience pain and suffer from comorbidities related to their bleeding disorder. Consequently, unemployment due to disability is prevalent among people with hemophilia. Objectives: To explore...
4.
Reding M, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, et al.
Drugs R D
. 2024 Aug;
24(3):359-381.
PMID: 39162954
Damoctocog alfa pegol (BAY 94-9027, Jivi), is a site-specifically PEGylated, extended half-life recombinant factor VIII (FVIII) that is approved in several European and non-European countries for on-demand treatment and prophylaxis...
5.
Holme P, Blatny J, Chowdary P, Lassila R, OConnell N, Hermans C, et al.
Haemophilia
. 2024 Jul;
30(5):1109-1114.
PMID: 38986684
Background: Treatment options for people with haemophilia are evolving at a rapid pace and a range of prophylactic treatment options using various technologies are currently available, each with their own...
6.
Reding M, Simpson M, Ducore J, Holme P, Maas Enriquez M, Mancuso M
Acta Haematol
. 2024 Apr;
148(1):58-67.
PMID: 38599195
Introduction: The phase 2/3 PROTECT VIII study demonstrated long-term efficacy and safety of damoctocog alfa pegol (BAY 94-9027; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to improve its...
7.
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Jorgensen O, Steineger J, Hillarp A, Pareli Waland E, Holme P, Heimdal K, et al.
Laryngoscope Investig Otolaryngol
. 2024 Feb;
9(1):e1196.
PMID: 38362186
Objectives: The objective of this study was twofold: to determine the prevalence of arterial and venous thromboembolic events in the Norwegian Hereditary Hemorrhagic Telangiectasia (HHT) population, and to explore potential...
8.
Holme P, Poulsen L, Tueckmantel C, Maas Enriquez M, Alvarez Roman M, De Cristofaro R
Haemophilia
. 2024 Jan;
30(2):388-394.
PMID: 38229269
Introduction: Damoctocog alfa pegol (BAY 94-9027, Jivi ) is an approved extended half-life factor VIII (FVIII) for treatment of previously treated patients with haemophilia A aged ≥12 years. We report...
9.
Astermark J, Baghaei F, Strandberg K, Toplican P, Birkedal M, Grahn E, et al.
Ther Adv Hematol
. 2023 Oct;
14:20406207231202306.
PMID: 37859645
Background: Despite improvements in hemophilia care, challenges remain, including treatment burden and impaired quality of life. Gene therapy may overcome these. However, its introduction presents a challenge. Objectives: To outline...
10.
Warlo E, Kalstad A, Myhre P, Solheim S, Arnesen H, Tveit A, et al.
Res Pract Thromb Haemost
. 2023 May;
7(4):100164.
PMID: 37255854
Background: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with...